Cardiogenic shock phenotypes and outcomes under percutaneous left ventricular support: results from a 9-year single-center real-world cohort

Background Refractory cardiogenic shock (CS) remains associated with unacceptably high mortality despite advances in intensive-care and coronary intervention strategies. Percutaneous left ventricular support using Impella is widely used, yet real-world outcomes may differ substantially by underlying shock etiology and phenotype. Methods We performed a retrospective single-center cohort study of adults treated with Impella 2.5/CP for refractory CS over a 9-year period. Patients were classified as acute coronary syndrome (ACS), dilated cardiomyopathy (DCM)/myocarditis, severe aortic stenosis (AS), sepsis-associated CS, or other causes. Endpoints were all-cause in-hospital and 12-month mortality. Multivariable logistic regression adjusted for age, sex, lactate, vasoactive score, Impella type was conducted; a sensitivity model additionally included creatinine. Results Among 409 patients (mean age 69.99 ± 11.56 years; 75.6% male), ACS was the leading phenotype ( n = 269), followed by DCM/myocarditis ( n = 53), AS ( n = 32), sepsis-associated CS ( n = 36), and other causes ( n = 19). Impella CP was used in 227 patients (55.5%). Overall in-hospital mortality was 48.9% and differed across phenotypes, being highest in sepsis-associated CS (80.6%; chi-squared p < 0.001). Sepsis remained independently associated with in-hospital death after adjustment (adjusted odds ratio 4.65, 95% CI 2.03–12.07, p = 0.0006) for major confounders; finding was consistent after additional adjustment for creatinine (adjusted odds ratio 4.17, 95% CI 1.63–12.26, p = 0.0023). Major bleeding occurred in 14.9%, limb ischemia in 11.7%, pseudoaneurysm in 4.9%, and stroke in 1.0% of the patients. Twelve-month survival analysis also demonstrated phenotype-dependent patterns (log-rank p < 0.01). Conclusion In refractory CS treated with Impella outcomes are strongly phenotype-dependent. Sepsis-associated CS represents an extreme-risk phenotype with poor short- and long-term survival, suggesting phenotype-guided patient selection and prospective validation of escalation strategies.

Authors

Institutions

Publication Details

Journal
Clinical Research in Cardiology
Published
2026-11-19
DOI
https://doi.org/10.1007/s00392-026-03055-6
Primary Topic
Mechanical Circulatory Support Devices
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cardiogenic shock phenotypes and outcomes under percutaneous left ventricular support: results from a 9-year single-center real-world cohort

Christian Waechter, Felix Ausbuettel, Julian Kreutz, Styliani Syntila et al.
Clinical Research in Cardiology
Mechanical Circulatory Support Devices
article

Cardiogenic shock phenotypes and outcomes under percutaneous left ventricular support: results from a 9-year single-center real-world cohort

Christian Waechter, Felix Ausbuettel, Julian Kreutz, Styliani Syntila, Harald Schuett, Harald Lapp, Bjoern Goebel, Birgit Markus, Georgios Chatzis, Bernhard Schieffer, Kiarash Sassani, Carlo-Federico Fichera, Fares Kano
article en

Abstract

Background Refractory cardiogenic shock (CS) remains associated with unacceptably high mortality despite advances in intensive-care and coronary intervention strategies. Percutaneous left ventricular support using Impella is widely used, yet real-world outcomes may differ substantially by underlying shock etiology and phenotype. Methods We performed a retrospective single-center cohort study of adults treated with Impella 2.5/CP for refractory CS over a 9-year period. Patients were classified as acute coronary syndrome (ACS), dilated cardiomyopathy (DCM)/myocarditis, severe aortic stenosis (AS), sepsis-associated CS, or other causes. Endpoints were all-cause in-hospital and 12-month mortality. Multivariable logistic regression adjusted for age, sex, lactate, vasoactive score, Impella type was conducted; a sensitivity model additionally included creatinine. Results Among 409 patients (mean age 69.99 ± 11.56 years; 75.6% male), ACS was the leading phenotype ( n = 269), followed by DCM/myocarditis ( n = 53), AS ( n = 32), sepsis-associated CS ( n = 36), and other causes ( n = 19). Impella CP was used in 227 patients (55.5%). Overall in-hospital mortality was 48.9% and differed across phenotypes, being highest in sepsis-associated CS (80.6%; chi-squared p < 0.001). Sepsis remained independently associated with in-hospital death after adjustment (adjusted odds ratio 4.65, 95% CI 2.03–12.07, p = 0.0006) for major confounders; finding was consistent after additional adjustment for creatinine (adjusted odds ratio 4.17, 95% CI 1.63–12.26, p = 0.0023). Major bleeding occurred in 14.9%, limb ischemia in 11.7%, pseudoaneurysm in 4.9%, and stroke in 1.0% of the patients. Twelve-month survival analysis also demonstrated phenotype-dependent patterns (log-rank p < 0.01). Conclusion In refractory CS treated with Impella outcomes are strongly phenotype-dependent. Sepsis-associated CS represents an extreme-risk phenotype with poor short- and long-term survival, suggesting phenotype-guided patient selection and prospective validation of escalation strategies.

Clinical Research in Cardiology
Philipps University of Marburg (DE), University of Münster (DE), Krankenhaus der Barmherzigen Brüder Trier (DE), Zentralklinik Bad Berka (DE), Kliniken des Landkreises Lörrach (DE)
Mechanical Circulatory Support Devices
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon